Italian clinical research in non-small-cell lung cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  Gridelli, Cesare ^a   Rossi, A ^a   Galetta, D ^b   Maione, P ^a   Ferrara, C ^a   Guerriero, C ^a   Del Gaizo, F ^a   Nicolella, D ^a   Colantuoni, G ^d   Gebbia, V ^c   Colucci, G ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c LA MADDALENA CANCER CENTER   (Italy)

^d NONE

Author keywords

Italian clinical research; Lung cancer; NSCLC

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMC C 225; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; ROFECOXIB; VINDESINE;

ADVANCED CANCER; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FATALITY; HEART INFARCTION; HUMAN; ITALY; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; POSTOPERATIVE CARE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW;

EID: 30644460382     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi919     Document Type: Article

References (52)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Borras JM, Fernandez E, Gonzalez JR et al. Lung cancer mortality in European regions (1955-1997). Ann Oncol 2003; 14: 159-161.
3. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol 2003; 4: 45-55.
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
5. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non small cell lung cancer. New Eng J Med 2000; 343: 1217-1222.
6. Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95: 1422-1424.
7. Waller D, Peake MD, Stephens RJ et al. Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26: 173-182.
8. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
9. Winton TL, Livingston R, Johnson D et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC) Intergroup JBR.10. Proc Am Soc Clin Oncol 2004; 23: 621s (Abstr 7018).
10. Strauss GM, Herndon J, Maddaus MA et al. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Oncol 2004; 23: 621s (Abstr 7019).
11. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-1721.
12. Hamada C, Ohta M, Wada H et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. Proc Am Soc Clin Oncol 2004; 23: 617s (Abstr 7002).
13. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330: 153-158.
14. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994; 86: 673-680.
15. Elias AD, Herndon J, Kumar P et al. A phase III comparison of "best local-regional therapy" with or without chemotherapy (CT) for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): Preliminary results. Proc Am Soc Clin Oncol 1997; 16: 448a (Abstr 1611).
16. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Onco12002; 20: 247-253.
17. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
18. Curran WJ Jr, Scott CB, Langer CJ et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin 2003; 22: 621 (Abstr 2499).
19. De Marinis F, Nelli F, Migliorino MR et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven stage IIIA(N2) nonsmall cell lung carcinoma: A phase II multi-center study. Cancer 2003; 98: 1707-1715.
20. Cappuzzo F, De Marinis F, Nelli F et al. Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. Lung Cancer 2003; 42: 355-361.
21. Scagliotti GV, Manegold C, Buchholz E et al. Randomized phase II study evaluating the feasibility of thoracic radiotherapy with or without weekly docetaxel (Taxotere) following induction chemotherapy with cisplatin (DDP) and docetaxel in unresectable stage IIIA/IIIB non-small cell lung cancer. Proc Am Soc Clin Onco12002; 21: 320a (Abstr 1279).
22. Gridelli C, Guida C, Barletta E et al. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: A phase I study. Lung Cancer 2000; 29: 131-137.
23. Trodella L, Granone P, Valente S et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 2002; 20: 804-810.
24. Crino L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522-3530.
25. Gebbia V, Galetta D, Riccardi R et al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: A prospective randomized study. Lung Cancer 2002; 37: 179-187.
26. Gebbia V, Galetta D, Caruso M et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: A prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003; 39: 179-189.
27. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-basd doublets in advanced non-small-cell lung cancer. J Clin Onco12002; 20: 4285-4291.
28. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478-1484.
29. Smit EF, van Meerbeeck JP, Lianes P et al. A phase III trial of European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003; 21: 3909-3917.
30. Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Onco12003; 21: 3025-3034.
31. Gridelli C. How to combine cytotoxic and cytostatic agents. Lung Cancer 2002; 38: S39.
32. Topol EJ. Failing the Public Health - Rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351: 1707.
33. Silverberg E. Cancer statistics. Cancer J Clin 1988; 38: 5-22.
34. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997; 33: 2313-2314.
35. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
36. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 2529-2536.
37. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
38. Le Chevalier T, Brisgand D, Douillard J-Y et al. Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin vs vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicentre trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
39. Depierre A, Chastang Cl, Quoix E et al. Vinorelbine vs vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial. Ann Oncol 1994; 5: 37-42.
40. Crawford J, O'Rourke M, Schiller JH et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996; 14: 2774-2784.
41. Pfister DG, Johnson DH, Azzoli CG et a1. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
42. Gridelli C, Rossi A, Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003; 22: 6629-6638.
43. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
44. Kris MG, Natale BR, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-2158.
45. Shepherd FA, Pereira J, Ciuleanu TE et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004; 22(14S): 622s (Abstr 7022).
46. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784.
47. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-794.
48. Scagliotti G, Rossi A, Novello S et al. Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: 633 (Abstr 7081).
49. Stahel R, Rossi A, Petruzelka L et al. Lessons from the 'Iressa' Expanded Access Programme: Gefitinib in special non-small-cell lung cancer patient populations. Br J Cancer 2003; 89 (Suppl 2): S19-S23.
50. Gridelli C, Maione P, Castaldo V et al. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003; 89: 1827-1829.
51. Cavina R, Soto Parra HJ, Zucali PA et al. ZD 1839 (Iressa) in elderly patients with progressive pretreated non-small cell lung cancer (NSCLC): results at the Istituto Clinico Humanitas, Rozzano, Milano. Lung Cancer 2003; 41 (Suppl 2): S248.
52. Cappuzzo F, Bartolini S, Ceresoli GL et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 2004; 90: 82-86.